Cargando…
An Adolescent Patient With Idiopathic Pulmonary Arterial Hypertension Weaned Off Intravenous Epoprostenol Following Treatment With Selexipag: A Case Report
Idiopathic pulmonary arterial hypertension (PAH) is a rare, progressive disease affecting the pulmonary arteries. Epoprostenol, a synthetic prostaglandin analog, is the most potent pharmacological treatment modality used in patients with PAH. However, it requires continuous intravenous infusion, whi...
Autores principales: | Chida-Nagai, Ayako, Tsujioka, Takao, Sasaki, Daisuke, Izumi, Gaku, Yamazawa, Hirokuni, Takeda, Atsuhito |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9247454/ https://www.ncbi.nlm.nih.gov/pubmed/35783314 http://dx.doi.org/10.3389/fped.2022.909595 |
Ejemplares similares
-
Left ventricular inflow obstruction due to a coronary arteriovenous fistula: a paediatric case report
por: Chida-Nagai, Ayako, et al.
Publicado: (2021) -
A Cardiac Arrest Case due to Left Coronary Artery Compression in Congenital Heart Disease-Associated Pulmonary Arterial Hypertension
por: Chida-Nagai, Ayako, et al.
Publicado: (2022) -
Pulmonary vasodilators can lead to various complications in pulmonary “arterial” hypertension associated with congenital heart disease
por: Chida-Nagai, Ayako, et al.
Publicado: (2020) -
A case of infantile Barth syndrome with severe heart failure: Importance of splicing variants in the TAZ gene
por: Takeda, Atsuhito, et al.
Publicado: (2023) -
Transitioning intravenous epoprostenol to oral selexipag in idiopathic pulmonary arterial hypertension: a case report
por: Alexandre, André, et al.
Publicado: (2023)